137 related articles for article (PubMed ID: 38907966)
1. Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.
Ferrari G; Kisinovsky I; Reisin R; Rozenfeld P; Neumann P; Finn V; Marchesoni C; Quieto P;
Medicina (B Aires); 2024; 84(3):516-525. PubMed ID: 38907966
[TBL] [Abstract][Full Text] [Related]
2. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
3. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
5. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
6. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
8. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
10. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
13. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
Ramaswami U; Beck M; Hughes D; Kampmann C; Botha J; Pintos-Morell G; West ML; Niu DM; Nicholls K; Giugliani R;
Drug Des Devel Ther; 2019; 13():3705-3715. PubMed ID: 31749608
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
15. Effects of Agalsidase Alfa Enzyme Replacement Therapy on Left Ventricular Hypertrophy on Electrocardiogram in a Female Patient with Fabry Disease.
Nakamura K; Morita H; Takaya Y; Saito Y; Miyoshi T; Morinaga H; Sugiyama H; Wada J; Ito H
Int Heart J; 2023 May; 64(3):502-505. PubMed ID: 37197914
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
18. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
19. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
[TBL] [Abstract][Full Text] [Related]
20. Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis.
Lee CL; Lin SP; Niu DM; Lin HY
Int J Med Sci; 2022; 19(1):126-131. PubMed ID: 34975306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
